Cynosure obtains FDA clearance to market SculpSure for non-invasive reduction of fat from the abdomen
Cynosure, Inc., a leader in laser- and light-based aesthetic treatments, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market SculpSure for non-invasive lipolysis of the abdomen. In May, the FDA cleared SculpSure for non-invasive lipolysis of the flanks.